Real-World data reveals how two prostate cancer drugs stack up
NCT ID NCT05968599
First seen Feb 27, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This study looked at medical records of over 2,700 men with advanced prostate cancer that no longer responds to hormone therapy. Researchers compared two common treatments, enzalutamide and abiraterone, to see which one helped men live longer and stay on treatment longer. The goal was to understand how these drugs work in everyday medical practice, not in a controlled trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Inc
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.